Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout

Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout

Abstract Background Allopurinol (ALP), a xanthine oxidase inhibitor, is a first line drug for the treatment of gout and hyperuricemia. Being the member of BCS class II drugs, ALP has solubility problem, which affects its bioavailability. Also, ALP has shorter half-life and showed GI related problems...

Full description

Bibliographic Details
Main Authors: Zakir Ali, Fakhar ud Din, Fatima Zahid, Saba Sohail, Basalat Imran, Salman Khan, Maimoona Malik, Alam Zeb, Gul Majid Khan
Format: Article
Language:English
Published: BMC 2022-11-01
Series:BMC Pharmacology and Toxicology
Subjects:
Allopurinol
Nanostructured lipid carriers
Anti-gout study
Transdermal
Online Access:https://doi.org/10.1186/s40360-022-00625-y

Internet

https://doi.org/10.1186/s40360-022-00625-y

Similar Items